News

For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

12th Dec 22

Pharmaxis Cancer Drug Pxs-5505 Profiled in Two Posters At American Society of Hematology Conference

  • Further analysis of interim data from 6 patients in phase 2 myelofibrosis study; PXS-5505 continues to exhibit an excellent safety profile with encouraging signs of clinical activity in patients ineligible for a JAK inhibitor.
  • Pharmaxis to discuss next steps in clinical development of PXS-5505 for myelofibrosis with FDA in Q1 2023.
  • Potential application for PXS-5505 in myelodysplastic syndrome highlighted by promising data released from pre-clinical studies of bone marrow samples from patients.
Read full media release - pdf
19th Oct 22

PXS announces positive interim data from myelofibrosis trial

  • PXS-5505 continues to exhibit an excellent safety profile with encouraging signs of clinical activity in patients’ ineligible for a JAK inhibitor.
  • 15 out of 24 patients recruited with full recruitment expected by year end and results in Q3 2023.
Read full media release - pdf
19th Oct 22

Pharmaxis Announces Two-Tranche Placement to Raise A$10 Million

  • A$10.0 million two-tranche placement to a small group of international and domestic institutional investors.
  • A$30m pro-forma cash balance post raising.
  • Funds raised will be used to advance the Company’s current clinical study in myelofibrosis, other clinical studies in or close to recruitment in scarring, liver cancer and Parkinson’s disease.
  • Placement announced in conjunction with positive interim data from Myelofibrosis Phase 2 cancer trial. Refer separate announcement dated 19 October 2022.
Read full media release - pdf